About Karus

At a glance

An experienced team delivering anti-cancer therapeutics with breakthrough potential

Karus Therapeutics is a clinical-stage biopharmaceutical company. We are developing precision medicines for cancer.

Our team

Our highly experienced management team has a track record of scientific and clinical excellence in small-molecule drug design and development. Our programs are underpinned by a broad, wholly-owned, intellectual property estate.

Our approach

Our orally-active small-molecule drugs have been designed and developed to be highly-selective therapies for cancer patients with unmet medical needs and limited treatment options.

Clinical Pipeline

We have two small molecule clinical candidates in Phase I studies, KA2507 and KA2237. By end-2019 we are planning to progress these to Phase II clinical trials. Pre-clinical data show that our innovative small-molecules have the potential to be used in combination with other therapies for the treatment of solid tumors and hematological cancers.

R&D

We invest in research and development of the highest quality and collaborate with leading academic centers of excellence. Our R&D program is focused on a new generation of brain-penetrant, non-genotoxic molecules targeting glioblastoma and other indications.

Strategic partnering

We seek strategic collaborations with leading companies who are commercializing innovative anti-cancer therapeutics.

Phase I clinical trials for KA22507 (NCT03008018) and KA2237 (NCT02679196) are currently underway in collaboration with The University of Texas MD Anderson Cancer Center.

Investors

We are supported by a syndicate of world-class life science investors from the US and Europe.